0 Replies
Stories include:
Another week, another RNAi delivery breakthrough for the Alnylam/MIT partnership. Last week, the Cambridge, MA-based company and its academic partner published new data describing a new approach for systemic delivery of RNAi therapeutics using "lipidoids" This week, they're approaching delivery of gene-silencing RNA using what they're calling "core-shell"... Contine Reading & Discuss→
0 Replies
PASADENA, Calif. - July 26, 2011 - Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity and regenerative medicine, today announced that Timothy J. Triche, M.D., Ph.D., Professor of Pathology and Pediatrics at the University of Southern California ('USC') Keck School of Medicine, has agreed... Contine Reading & Discuss→
0 Replies
Boulder, CO, July 26, 2011 – miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients’ lives by developing innovative microRNA (miRNA)-based therapeutics for cardiovascular and muscle disease, announced today that new preclinical data published in the online edition of Circulation Research suggests that microRNA-15 (miR-15) inhibits cardiomyogenesis, the process... Contine Reading & Discuss→
0 Replies
Stories include:
Gene-silencing siRNA technology has failed to live up to its original hype largely because of problems delivering short interfering RNA to the precise spot where it's needed. Alnylam Pharmaceuticals, a Cambridge, MA company focused on RNAi-based therapeutics, together with partners at MIT, think they've found a solution. A... Contine Reading & Discuss→
0 Replies
Stories include:
@FiercePharma: Novartis mulls IPO on China's planned int'l board. News
GlaxoSmithKline and Human Genome Sciences have been boosted by another approval for their lupus drug Benlysta, this time in Canada. Piece Contine Reading & Discuss→
0 Replies
Stories include:
@FierceBiotech: Superbug antibiotics: New drugs advance amid R&D investment shortfall. Special Report
Xconomy caught up with Idera Pharmaceuticals ($IDRA) after the developer of drugs that target Toll-like receptors suffered a setback last week in its collaboration with German drug maker Merck KGaA. Idera, as the story notes, is... Contine Reading & Discuss→
0 Replies
WORCESTER, Mass.–(BUSINESS WIRE)– – RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using targeted biotherapeutics, announced today that it expanded its patent portfolio with additional patents covering worldwide rights to develop and commercialize NeuVax™ (E75). The patents... Contine Reading & Discuss→
0 Replies
Stories include:
Alnylam Pharmaceuticals, a Cambridge, MA company focused on RNAi-based therapeutics, has filed an application to initiate Phase I trials for ALN-PCS, its second-generation lipid-nanoparticle delivery technology to treat severe hypercholesterolemia, or high cholesterol in the blood.
"We are excited about the potential for ALN-PCS to make an impact... Contine Reading & Discuss→
